AUROPHARMA quarterly results

Q1 FY27 · Apr–Jun 2026

₹ crore	Q1 FY27	Q1 FY26	Change
Revenue	9,150	7,868	+16.3%
EBITDA	1,881	1,603	+17.3%
EBITDA margin	20.6%	20.4%	+0.2 pts
Profit before tax	1,517	1,205	+25.9%
Net profit	1,032	824	+25.2%
EPS	₹17.86	₹14.20	+25.8%

Every quarter

₹ crore except per share

Tap a line for its trend	Q1 FY27Jun 2026	Q4 FY26Mar 2026	Q3 FY26Dec 2025	Q2 FY26Sep 2025	Q1 FY26Jun 2025	Q4 FY25Mar 2025	Q3 FY25Dec 2024	Q2 FY25Sep 2024	Q1 FY25Jun 2024	Q4 FY24Mar 2024	Q3 FY24Dec 2023	Q2 FY24Sep 2023	Earlier quartersAlpha Plus

Expenses
	9,150	8,853	8,646	8,286	7,868	8,382	7,979	7,796	7,567	7,580	7,352	7,219	Earlier quartersEvery year the company has filed comes with Alpha Plus.
	264	117	188	121	105	135	157	136	221	136	163	187
	9,415	8,970	8,834	8,406	7,973	8,517	8,136	7,932	7,788	7,716	7,514	7,406
	2,894	2,505	2,755	2,510	2,535	2,800	2,729	2,742	2,467	2,635	2,676	2,709
	932	931	893	846	808	636	824	747	680	786	776	631
	−199	−7.8	−166	−17.0	−104	−7.8	−237	−279	−74.0	−360	−301	−103
	1,480	1,374	1,310	1,277	1,229	1,163	1,132	1,109	1,072	1,026	990	955
	102	98.2	92.8	95.2	97.8	115	118	113	111	89.4	75.6	68.2
	487	479	465	429	406	444	419	382	404	354	423	418
	2,162	2,298	2,081	1,991	1,797	2,000	1,954	1,910	1,803	1,820	1,610	1,654
	7,858	7,677	7,430	7,132	6,769	7,150	6,938	6,725	6,463	6,351	6,249	6,332
	1,881	1,753	1,773	1,678	1,603	1,792	1,578	1,566	1,620	1,673	1,601	1,373
	1,394	1,274	1,309	1,249	1,197	1,347	1,159	1,184	1,215	1,318	1,178	956
Profit
	1,557	1,293	1,403	1,274	1,205	1,367	1,198	1,207	1,325	1,365	1,265	1,075
	−40.2	0.0	−65.3	0.0	0.0	0.0	0.0	0.0	0.0	−122	0.0	0.0
	1,517	1,293	1,338	1,274	1,205	1,367	1,198	1,207	1,325	1,243	1,265	1,075
	610	399	383	463	491	431	498	322	449	571	385	482
	−127	−29.3	45.4	−35.2	−108	1.8	−144	68.4	−43.6	−248	−62.2	−158
	483	370	429	428	383	432	354	391	406	323	322	324
	−1.5	−2.4	0.4	1.7	1.9	−32.2	1.6	0.3	−1.4	−12.7	−2.6	0.9
	1,032	921	910	848	824	903	846	817	918	907	940	752
	1,034	923	909	846	822	935	844	817	920	920	943	751
	−46.9	791	228	541	406	140	−65.3	270	−41.1	−111	189	51.4
	985	1,711	1,138	1,389	1,230	1,042	780	1,087	877	797	1,129	803
	1,033	921	910	848	825	903	855	817	919	909	936	757
	−0.5	−0.4	−0.5	−0.3	−0.6	−0.6	−0.2	−0.4	−1.0	−1.4	3.7	−5.2
Per share
	₹17.86	₹15.86	₹15.67	₹14.61	₹14.20	₹15.56	₹14.56	₹14.00	₹15.69	₹15.51	₹16.04	₹12.83
	₹17.86	₹15.86	₹15.67	₹14.61	₹14.20	₹15.56	₹14.56	₹14.00	₹15.69	₹15.51	₹16.04	₹12.83
Other comprehensive income — detail
	−46.9	791	228	541	406	140	—	—	—	—	—	—
	−6.0	14.7	−3.1	0.3	−1.0	−3.5	−2.1	−2.5	−0.4	−11.1	1.8	−3.5
	0.0	3.6	−0.6	0.1	−0.3	−0.6	—	—	—	—	—	—
	—	—	—	—	—	—	−0.6	−0.8	−0.1	−1.9	−0.4	0.6
	−40.9	779	230	541	407	143	−63.8	272	−40.8	−101	187	55.5
	986	1,712	1,138	1,390	1,231	1,043	781	1,088	878	798	1,125	809
	−0.5	−0.4	−0.5	−0.3	−0.6	−0.7	−0.2	−0.4	−1.0	−1.4	3.7	−5.2
Per share — as-filed variants
	₹17.86	₹15.86	₹15.67	₹14.61	₹14.20	₹15.56	₹14.56	₹14.00	₹15.69	₹15.51	₹16.04	₹12.83
	₹17.86	₹15.86	₹15.67	₹14.61	₹14.20	₹15.56	₹14.56	₹14.00	₹15.69	₹15.51	₹16.04	₹12.83
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	5,523	5,424	5,165	4,947	4,629	4,954	4,663	4,586	4,494	4,519	4,201	3,983
	60.4%	61.3%	59.7%	59.7%	58.8%	59.1%	58.4%	58.8%	59.4%	59.6%	57.1%	55.2%
Adjusted (ex-exceptional items) — derived
	1,557	1,293	1,403	1,274	1,205	1,367	1,198	1,207	1,325	1,365	1,265	1,075
	−40.2	0.0	−65.3	0.0	0.0	0.0	0.0	0.0	0.0	−122	0.0	0.0
	1,059	921	954	848	824	903	846	817	918	998	940	752
	₹18.33	₹15.86	₹16.43	₹14.61	₹14.20	₹15.56	₹14.56	₹14.00	₹15.69	₹17.06	₹16.04	₹12.83

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AUROPHARMA₹1,644.80

AUROPHARMA

Annual Quarterly₹ CroreMcap ₹95,530 Cr

View

In ₹ Crore except Per Share 3 Months Ending	Q2 FY24 30/09/2023	Q3 FY24 31/12/2023	Q4 FY24 31/03/2024	Q1 FY25 30/06/2024	Q2 FY25 30/09/2024	Q3 FY25 31/12/2024	Q4 FY25 31/03/2025	Q1 FY26 30/06/2025	Q2 FY26 30/09/2025	Q3 FY26 31/12/2025	Q4 FY26 31/03/2026	Q1 FY27 30/06/2026
Revenue from Operations	7,219.4	7,351.8	7,580.2	7,567.0	7,796.1	7,978.5	8,382.1	7,868.1	8,285.7	8,645.9	8,853.3	9,150.4
Other Income	187.0	162.5	135.6	220.9	136.0	157.3	134.8	105.3	120.6	187.6	117.0	264.2
Total Income	7,406.4	7,514.3	7,715.8	7,788.0	7,932.1	8,135.8	8,516.9	7,973.4	8,406.3	8,833.5	8,970.4	9,414.6
Expenses
+ Cost of Materials Consumed	2,708.9	2,675.5	2,634.9	2,466.7	2,741.9	2,728.7	2,799.5	2,535.2	2,509.8	2,754.9	2,505.4	2,894.4
+ Purchases of Stock-in-Trade	631.1	775.8	786.0	680.0	747.0	823.9	636.2	807.8	846.1	892.7	931.5	931.8
+ Changes in Inventories	-103.2	-300.7	-360.0	-74.0	-278.6	-237.2	-7.8	-103.7	-17.0	-166.3	-7.8	-199.2
+ Employee Benefit Expense	955.0	989.7	1,026.3	1,072.0	1,109.5	1,131.6	1,162.6	1,228.8	1,277.3	1,310.1	1,374.0	1,480.2
+ Finance Costs	68.2	75.6	89.4	111.0	112.7	118.5	115.0	97.8	95.2	92.8	98.2	101.7
+ Depreciation & Amortisation	417.5	423.3	354.3	404.2	382.3	418.5	444.4	405.7	429.2	464.7	478.6	486.8
+ Other Expenses	1,654.3	1,610.2	1,820.1	1,802.8	1,910.2	1,953.6	1,999.7	1,797.1	1,991.4	2,081.3	2,297.5	2,162.2
Total Expenses	6,331.7	6,249.3	6,351.1	6,462.7	6,724.9	6,937.6	7,149.7	6,768.6	7,132.0	7,430.1	7,677.3	7,857.8
EBITDA	1,373.4	1,601.3	1,672.8	1,619.6	1,566.1	1,578.0	1,791.9	1,603.0	1,678.1	1,773.3	1,752.8	1,881.1
EBIT	955.9	1,178.0	1,318.5	1,215.4	1,183.9	1,159.5	1,347.5	1,197.3	1,248.9	1,308.6	1,274.2	1,394.2
Profit
PBT before Exceptional Items	1,074.7	1,265.0	1,364.7	1,325.3	1,207.2	1,198.3	1,367.3	1,204.9	1,274.3	1,403.5	1,293.0	1,556.8
+ Exceptional Items	0.0	0.0	-122.1	0.0	0.0	0.0	0.0	0.0	0.0	-65.3	0.0	-40.2
Pretax Income	1,074.7	1,265.0	1,242.6	1,325.3	1,207.2	1,198.3	1,367.3	1,204.9	1,274.3	1,338.2	1,293.0	1,516.6
+ Current Tax	481.8	384.6	570.6	449.3	322.1	498.1	430.5	490.7	463.0	383.4	399.0	610.0
+ Deferred Tax	-158.1	-62.2	-248.1	-43.6	68.4	-143.8	1.8	-108.1	-35.2	45.4	-29.3	-127.0
Tax Expense	323.7	322.5	322.6	405.7	390.5	354.3	432.3	382.6	427.8	428.7	369.8	483.1
+ Share of Associates & JVs	0.9	-2.6	-12.7	-1.4	0.3	1.6	-32.2	1.9	1.7	0.4	-2.4	-1.5
Net Income	751.9	940.0	907.4	918.2	817.0	845.6	902.8	824.2	848.1	909.8	920.8	1,032.0
+ Net Income — Continuing Ops	751.0	942.6	920.0	919.6	816.7	844.0	935.0	822.3	846.5	909.4	923.3	1,033.6
+ Other Comprehensive Income	51.4	188.7	-110.6	-41.1	270.3	-65.3	139.7	405.8	541.1	227.7	790.6	-46.9
Total Comprehensive Income	803.3	1,128.7	796.8	877.2	1,087.2	780.3	1,042.5	1,230.0	1,389.2	1,137.5	1,711.4	985.2
Net Income to Common	757.2	936.3	908.8	919.2	817.4	854.8	903.5	824.8	848.5	910.3	921.3	1,032.6
Minority Interest	-5.2	3.7	-1.4	-1.0	-0.4	-0.2	-0.6	-0.6	-0.3	-0.5	-0.4	-0.5
Per Share
Basic EPS	12.83	16.04	15.51	15.69	14.00	14.56	15.56	14.20	14.61	15.67	15.86	17.86
Diluted EPS	12.83	16.04	15.51	15.69	14.00	14.56	15.56	14.20	14.61	15.67	15.86	17.86
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	—	—	—	—	139.7	405.8	541.1	227.7	790.6	-46.9
+ Items NOT to be Reclassified to P&L	-3.5	1.8	-11.1	-0.4	-2.5	-2.1	-3.5	-1.0	0.3	-3.1	14.7	-6.0
+ Tax on Items NOT to be Reclassified	—	—	—	—	—	—	-0.6	-0.3	0.1	-0.6	3.6	0.0
+ Tax on Items NOT to be Reclassified — alt tag	0.6	-0.4	-1.9	-0.1	-0.8	-0.6	—	—	—	—	—	—
+ Items to be Reclassified to P&L	55.5	186.5	-101.4	-40.8	272.0	-63.8	142.5	406.5	540.9	230.2	779.4	-40.9
Comprehensive Income — Owners of Parent	808.6	1,125.0	798.2	878.2	1,087.7	780.5	1,043.1	1,230.6	1,389.5	1,138.0	1,711.8	985.7
Comprehensive Income — Non-controlling Interests	-5.2	3.7	-1.4	-1.0	-0.4	-0.2	-0.7	-0.6	-0.3	-0.5	-0.4	-0.5
Per Share — as-filed variants
Basic EPS — Continuing Operations	12.83	16.04	15.51	15.69	14.00	14.56	15.56	14.20	14.61	15.67	15.86	17.86
Diluted EPS — Continuing Operations	12.83	16.04	15.51	15.69	14.00	14.56	15.56	14.20	14.61	15.67	15.86	17.86
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	3,982.7	4,201.2	4,519.3	4,494.3	4,585.8	4,663.1	4,954.2	4,628.9	4,946.8	5,164.7	5,424.3	5,523.4
Gross Margin %	55.17	57.15	59.62	59.39	58.82	58.45	59.10	58.83	59.70	59.74	61.27	60.36
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	1,074.7	1,265.0	1,364.7	1,325.3	1,207.2	1,198.3	1,367.3	1,204.9	1,274.3	1,403.5	1,293.0	1,556.8
− Exceptional Items (reconciliation)	0.0	0.0	-122.1	0.0	0.0	0.0	0.0	0.0	0.0	-65.3	0.0	-40.2
Net Income Adj (tax-effected)	751.9	940.0	997.8	918.2	817.0	845.6	902.8	824.2	848.1	954.2	920.8	1,059.4
EPS Adj	12.83	16.04	17.06	15.69	14.00	14.56	15.56	14.20	14.61	16.43	15.86	18.33
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00
Paid Up Equity Capital	58.6	58.6	58.6	58.6	58.1	58.1	58.1	58.1	58.1	58.1	58.1	57.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.

Aurobindo Pharma Q2 FY27 results date

Aurobindo Pharma (NSE: AUROPHARMA) will announce its Q2 FY27 results (July–September 2026) on Wednesday, 4 November 2026, according to the board-meeting notice it filed on 26 October 2026, which also lists a dividend. Its latest results are for Q1 FY27 (April–June 2026). Consolidated net profit attributable to shareholders was ₹1,033 crore, up 25.2% from ₹825 crore in Q1 FY26 and up 12.1% from ₹921 crore in Q4 FY26. Revenue from operations was ₹9,150 crore, up 16.3% year on year and up 3.4% from the previous quarter.

Board-meeting notice filed: 26 October 2026
Q2 FY26 results (a year earlier): 5 November 2025
Q1 FY27 results (the latest): 5 August 2026

Latest results: Q1 FY27 (Apr–Jun 2026) · consolidated

Q2 FY27 results date: 4 November 2026Wednesday · notice filed 26 Oct
Q1 FY27 net profit: ₹1,033 Cr+25.2% vs Q1 FY26+12.1% vs Q4 FY26
Q1 FY27 revenue: ₹9,150 Cr+16.3% vs Q1 FY26+3.4% vs Q4 FY26
Q1 FY27 operating margin: 15.2%unchanged vs Q1 FY26+0.8 pts vs Q4 FY26
Q2 FY26 net profit (a year earlier): ₹848 CrRevenue ₹8,286 Cr
Q1 FY27 EPS (basic): ₹17.86

Questions

When will Aurobindo Pharma announce its Q2 FY27 results?

On 4 November 2026, the date of the board meeting called to approve them (notice filed with the exchanges on 26 October 2026). Last year it reported Q2 FY26 on 5 November 2025.

What will Aurobindo Pharma's Q2 FY27 results be compared with?

With the same quarter a year earlier, Q2 FY26 (July–September 2025), when consolidated net profit attributable to shareholders was ₹848 crore and revenue from operations ₹8,286 crore. The latest quarter, Q1 FY27, had a net profit of ₹1,033 crore and revenue of ₹9,150 crore.

What were Aurobindo Pharma's Q1 FY27 results?

Consolidated net profit attributable to shareholders was ₹1,033 crore, up 25.2% from ₹825 crore in Q1 FY26 and up 12.1% from ₹921 crore in Q4 FY26. Revenue from operations was ₹9,150 crore, up 16.3% year on year and up 3.4% from the previous quarter.

How has Aurobindo Pharma's profit changed over the last four quarters?

Net profit attributable to shareholders by quarter: ₹848 crore in Q2 FY26, ₹910 crore in Q3 FY26, ₹921 crore in Q4 FY26 and ₹1,033 crore in Q1 FY27. That is ₹3,713 crore over the four quarters, up 9.2% from ₹3,400 crore in the four quarters before. Revenue from operations: ₹8,286 crore, ₹8,646 crore, ₹8,853 crore and ₹9,150 crore.

What was Aurobindo Pharma's net profit in FY26?

Consolidated net profit attributable to shareholders was ₹3,505 crore in FY26 (April 2025–March 2026), up 0.5% from ₹3,486 crore in FY25. It was ₹3,173 crore in FY24 and ₹1,928 crore in FY23: up 81.8% over three years, 22.1% a year on average.

What was Aurobindo Pharma's revenue in FY26?

Revenue from operations was ₹33,653 crore in FY26 (April 2025–March 2026), up 6.1% from ₹31,724 crore in FY25. It was ₹29,002 crore in FY24 and ₹24,855 crore in FY23: up 35.4% over three years, 10.6% a year on average.

Where do these Aurobindo Pharma figures come from?

From Aurobindo Pharma's own consolidated results filings to NSE, in ₹ crore as filed; the date from its board-meeting notices.

Consolidated figures from the company's filings to NSE. Every company's results dates this season are in the Q2 FY27 results calendar, part of Alpha Plus.